California State Teachers Retirement System lessened its stake in shares of Repligen Corporation (NASDAQ:RGEN) by 8.7% in the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 60,748 shares of the biotechnology company’s stock after selling 5,756 shares during the period. California State Teachers Retirement System owned approximately 0.16% of Repligen Corporation worth $2,517,000 at the end of the most recent reporting period.
A number of other hedge funds also recently bought and sold shares of the stock. BlackRock Inc. increased its position in Repligen Corporation by 3.7% during the 2nd quarter. BlackRock Inc. now owns 4,834,853 shares of the biotechnology company’s stock valued at $200,355,000 after buying an additional 170,551 shares in the last quarter. TimesSquare Capital Management LLC increased its holdings in shares of Repligen Corporation by 19.8% in the 2nd quarter. TimesSquare Capital Management LLC now owns 2,361,270 shares of the biotechnology company’s stock worth $97,851,000 after purchasing an additional 390,545 shares in the last quarter. Vanguard Group Inc. increased its holdings in shares of Repligen Corporation by 9.7% in the 2nd quarter. Vanguard Group Inc. now owns 1,984,393 shares of the biotechnology company’s stock worth $82,233,000 after purchasing an additional 175,191 shares in the last quarter. FMR LLC increased its holdings in shares of Repligen Corporation by 6.2% in the 2nd quarter. FMR LLC now owns 1,334,090 shares of the biotechnology company’s stock worth $55,285,000 after purchasing an additional 78,060 shares in the last quarter. Finally, Conestoga Capital Advisors LLC increased its holdings in shares of Repligen Corporation by 6.3% in the 2nd quarter. Conestoga Capital Advisors LLC now owns 1,291,805 shares of the biotechnology company’s stock worth $53,532,000 after purchasing an additional 75,995 shares in the last quarter. 96.47% of the stock is owned by institutional investors.
ILLEGAL ACTIVITY WARNING: This piece was originally posted by Chaffey Breeze and is the property of of Chaffey Breeze. If you are viewing this piece on another domain, it was illegally stolen and republished in violation of United States & international trademark and copyright legislation. The correct version of this piece can be accessed at https://www.chaffeybreeze.com/2017/11/12/california-state-teachers-retirement-system-has-2-52-million-position-in-repligen-corporation-rgen.html.
A number of analysts have commented on RGEN shares. Jefferies Group LLC reissued a “hold” rating and issued a $40.00 target price on shares of Repligen Corporation in a report on Thursday, September 14th. William Blair started coverage on Repligen Corporation in a report on Friday, July 21st. They issued an “outperform” rating for the company. Zacks Investment Research raised Repligen Corporation from a “hold” rating to a “buy” rating and set a $43.00 target price for the company in a report on Thursday, October 5th. First Analysis raised Repligen Corporation from an “equal weight” rating to an “overweight” rating and set a $47.00 target price for the company in a report on Monday, October 2nd. Finally, Stephens reissued an “overweight” rating and issued a $50.00 target price on shares of Repligen Corporation in a report on Tuesday, September 26th. Two investment analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. The company has a consensus rating of “Buy” and a consensus price target of $45.40.
Shares of Repligen Corporation (RGEN) opened at $34.72 on Friday. The company has a market capitalization of $1,512.79, a price-to-earnings ratio of 59.87, a price-to-earnings-growth ratio of 2.31 and a beta of 1.05. Repligen Corporation has a fifty-two week low of $28.48 and a fifty-two week high of $46.81. The company has a quick ratio of 10.29, a current ratio of 11.87 and a debt-to-equity ratio of 0.51.
Repligen Corporation (NASDAQ:RGEN) last released its quarterly earnings results on Thursday, November 9th. The biotechnology company reported $0.15 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.11 by $0.04. The firm had revenue of $36.58 million for the quarter, compared to the consensus estimate of $35.69 million. Repligen Corporation had a return on equity of 11.78% and a net margin of 16.93%. The company’s revenue for the quarter was up 48.2% on a year-over-year basis. During the same period last year, the business posted $0.08 EPS. sell-side analysts expect that Repligen Corporation will post 0.6 earnings per share for the current year.
About Repligen Corporation
Repligen Corporation is a bioprocessing company. The Company is focused on the development, manufacture and commercialization of products used to improve the interconnected phases of the biological drug manufacturing process. The Company’s portfolio includes protein products, chromatography products, and filtration products.
Want to see what other hedge funds are holding RGEN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Repligen Corporation (NASDAQ:RGEN).
Receive News & Ratings for Repligen Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repligen Corporation and related companies with MarketBeat.com's FREE daily email newsletter.